Hypertriglyceridaemia and risk of coronary artery disease

[1]  M. Shao,et al.  Non-HDL Cholesterol and Triglycerides: Implications for Coronary Atheroma Progression and Clinical Events , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[2]  I. Graham.  2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. , 2016, European heart journal.

[3]  J. Lima,et al.  Sugar-sweetened carbonated beverage consumption and coronary artery calcification in asymptomatic men and women. , 2016, American heart journal.

[4]  A. Wierzbicki,et al.  Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia , 2016, Expert opinion on biological therapy.

[5]  B. Staels,et al.  The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis. , 2016, Atherosclerosis.

[6]  A. Nakashima,et al.  Relationship between serum triglyceride levels and endothelial function in a large community-based study. , 2016, Atherosclerosis.

[7]  S. Yamashita,et al.  Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. , 2016, Atherosclerosis.

[8]  Xiaona Wang,et al.  Triglycerides are a predictive factor for arterial stiffness: a community-based 4.8-year prospective study , 2016, Lipids in Health and Disease.

[9]  P. Toth.  Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease , 2016, Vascular health and risk management.

[10]  J. Kastelein,et al.  Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia , 2016, Cardiology.

[11]  P. Barter,et al.  A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia. , 2016, The American journal of cardiology.

[12]  F. Kronenberg,et al.  Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Med , 2016, Clinical chemistry.

[13]  J. Zamorano,et al.  Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. , 2016, European heart journal supplements : journal of the European Society of Cardiology.

[14]  J. Witztum,et al.  Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results1 , 2016, Journal of Lipid Research.

[15]  Rajiv,et al.  Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. , 2016, The New England journal of medicine.

[16]  J. Heeren,et al.  FGF21 Lowers Plasma Triglycerides by Accelerating Lipoprotein Catabolism in White and Brown Adipose Tissues. , 2016, Cell metabolism.

[17]  Alexander E. Lopez,et al.  Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease. , 2016, The New England journal of medicine.

[18]  A. Tenenbaum,et al.  Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two–Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry , 2016, Circulation. Cardiovascular quality and outcomes.

[19]  B. Nordestgaard.  Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. , 2016, Circulation research.

[20]  Sanghoon Moon,et al.  Genome-wide association study of serum lipids confirms previously reported associations as well as new associations of common SNPs within PCSK7 gene with triglyceride , 2016, Journal of Human Genetics.

[21]  J. Mckenney,et al.  National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. , 2015, Journal of clinical lipidology.

[22]  Ž. Reiner.  Management of patients with familial hypercholesterolaemia , 2015, Nature Reviews Cardiology.

[23]  G. Norata,et al.  Apolipoprotein C-III: From Pathophysiology to Pharmacology. , 2015, Trends in pharmacological sciences.

[24]  J. Zamorano,et al.  A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. , 2015, Atherosclerosis. Supplements.

[25]  D. Gaudet,et al.  Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. , 2015, The New England journal of medicine.

[26]  Jonathan C. Cohen,et al.  Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion1[S] , 2015, Journal of Lipid Research.

[27]  Dirk De Bacquer,et al.  Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology. , 2015, Atherosclerosis.

[28]  G. Sulo,et al.  Non-fasting triglycerides predict incident acute myocardial infarction among those with favourable HDL-cholesterol: Cohort Norway* , 2015, European journal of preventive cardiology.

[29]  S. Subramanian,et al.  Genetic Disorders of Triglyceride Metabolism , 2015 .

[30]  D. Demicco,et al.  Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. , 2015, Journal of the American College of Cardiology.

[31]  Young-Hak Kim,et al.  Serum Triglyceride Levels and Cardiovascular Disease Events in Koreans , 2015, Cardiology.

[32]  Ž. Reiner.  Are Elevated Serum Triglycerides Really a Risk Factor for Coronary Artery Disease? , 2015, Cardiology.

[33]  Ž. Reiner,et al.  Adverse effects of statins - myths and reality. , 2015, Current pharmaceutical design.

[34]  D. Gaudet,et al.  Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome , 2015, Lipids in Health and Disease.

[35]  D. Rader,et al.  Triglyceride-rich lipoproteins and coronary artery disease risk: new insights from human genetics. , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[36]  D. Gaudet,et al.  Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. , 2014, Journal of the American College of Cardiology.

[37]  A. Tenenbaum,et al.  Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor , 2014, Cardiovascular Diabetology.

[38]  K. Yamagishi,et al.  Fasting and non-fasting triglycerides and risk of ischemic cardiovascular disease in Japanese men and women: the Circulatory Risk in Communities Study (CIRCS). , 2014, Atherosclerosis.

[39]  J. Mckenney,et al.  National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. , 2014, Journal of clinical lipidology.

[40]  P. Amarenco,et al.  Residual Microvascular Risk in Type 2 Diabetes in 2014: Is it Time for a Re-Think? A Perspective from the Residual Risk Reduction Initiative (R3i) , 2014 .

[41]  Anette Varbo,et al.  Triglycerides and cardiovascular disease , 2014, The Lancet.

[42]  J. Borén,et al.  The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. , 2014, The lancet. Diabetes & endocrinology.

[43]  M. Linton,et al.  Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor–Dependent and –Independent Mechanisms , 2014, Circulation.

[44]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[45]  D. Goff,et al.  2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Journal of the American College of Cardiology.

[46]  M. Reilly,et al.  Differential Association of Plasma Angiopoietin-Like Proteins 3 and 4 With Lipid and Metabolic Traits , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[47]  B. Nordestgaard,et al.  Low nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study. , 2014, Clinical chemistry.

[48]  J. Borén,et al.  Postprandial hypertriglyceridemia as a coronary risk factor. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[49]  T. Lüscher,et al.  The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. , 2014, European heart journal.

[50]  Tom R. Gaunt,et al.  Mendelian randomization of blood lipids for coronary heart disease , 2014, European heart journal.

[51]  F. Sacks,et al.  Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes Mellitus: A Global Case–Control Study in 13 Countries , 2013, Circulation.

[52]  G. De Backer,et al.  Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey. , 2013, Atherosclerosis.

[53]  M. Munger,et al.  Icosapent Ethyl for Treatment of Elevated Triglyceride Levels , 2013, The Annals of pharmacotherapy.

[54]  S. Grundy.  An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia. , 2013, Journal of clinical lipidology.

[55]  Ying I. Wang,et al.  Triglyceride-Rich Lipoprotein Modulates Endothelial Vascular Cell Adhesion Molecule (VCAM)-1 Expression via Differential Regulation of Endoplasmic Reticulum Stress , 2013, PloS one.

[56]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[57]  Tanya M. Teslovich,et al.  Common variants associated with plasma triglycerides and risk for coronary artery disease , 2013, Nature Genetics.

[58]  K. Gohil,et al.  Induction of ATF3 Gene Network by Triglyceride-Rich Lipoprotein Lipolysis Products Increases Vascular Apoptosis and Inflammation , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[59]  Ž. Reiner.  Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. , 2013, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[60]  Ž. Reiner.  Statins in the primary prevention of cardiovascular disease , 2013, Nature Reviews Cardiology.

[61]  Richard G. Lee,et al.  Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans , 2013, Circulation research.

[62]  V. Perkovic,et al.  Omega 3 Fatty Acids and Cardiovascular Outcomes: Systematic Review and Meta-Analysis , 2012, Circulation. Cardiovascular quality and outcomes.

[63]  M. Carroll,et al.  Trends in lipids and lipoproteins in US adults, 1988-2010. , 2012, JAMA.

[64]  H. Heidbuchel,et al.  Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR (Part II) , 2012, European journal of preventive cardiology.

[65]  Ž. Reiner,et al.  Dyslipidemias in the Prevention of Cardiovascular Disease: Risks and Causality , 2012, Current Cardiology Reports.

[66]  T. Olivecrona,et al.  Inactivation of lipoprotein lipase occurs on the surface of THP-1 macrophages where oligomers of angiopoietin-like protein 4 are formed. , 2012, Biochemical and biophysical research communications.

[67]  R. Hegele,et al.  Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia , 2012, Journal of internal medicine.

[68]  D. Gaudet,et al.  Gene therapy for lipoprotein lipase deficiency , 2012, Current opinion in lipidology.

[69]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[70]  Jun Liu,et al.  Impact of diabetes, high triglycerides and low HDL cholesterol on risk for ischemic cardiovascular disease varies by LDL cholesterol level: a 15-year follow-up of the Chinese Multi-provincial Cohort Study. , 2012, Diabetes research and clinical practice.

[71]  Walter C Willett,et al.  Sweetened Beverage Consumption, Incident Coronary Heart Disease, and Biomarkers of Risk in Men , 2012, Circulation.

[72]  É. Thorin.  Vascular disease risk in patients with hypertriglyceridemia: endothelial progenitor cells, oxidative stress, accelerated senescence, and impaired vascular repair. , 2011, The Canadian journal of cardiology.

[73]  V. Salomaa,et al.  An Increased Burden of Common and Rare Lipid-Associated Risk Alleles Contributes to the Phenotypic Spectrum of Hypertriglyceridemia , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[74]  P. Kolh,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.

[75]  Moshe Levi,et al.  Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. , 2011, Circulation.

[76]  J. Borén,et al.  Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management , 2011, European heart journal.

[77]  Henry N. Ginsberg,et al.  The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid Trial , 2011, Diabetes Care.

[78]  Ž. Reiner,et al.  Physicians' perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey. , 2010, Atherosclerosis.

[79]  Ž. Reiner,et al.  Public perceptions of cardiovascular risk factors in Croatia: the PERCRO survey. , 2010, Preventive medicine.

[80]  F. Sacks,et al.  Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. , 2010, The American journal of cardiology.

[81]  F. Sacks,et al.  Combination lipid therapy in type 2 diabetes. , 2010, The New England journal of medicine.

[82]  V. Salomaa,et al.  Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia , 2010, Nature Genetics.

[83]  Lukasz Januszkiewicz.  [The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus]. , 2010, Kardiologia polska.

[84]  D. Grobbee,et al.  Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis , 2010, The Lancet.

[85]  J. Danesh,et al.  Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies , 2010, The Lancet.

[86]  John B Buse,et al.  Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[87]  Ž. Reiner.  Combined therapy in the treatment of dyslipidemia , 2010, Fundamental & clinical pharmacology.

[88]  J. Danesh,et al.  Major lipids, apolipoproteins, and risk of vascular disease. , 2009, JAMA.

[89]  S. Grundy,et al.  Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. , 2009, The American journal of cardiology.

[90]  R. Eckel,et al.  Lipoprotein lipase: from gene to obesity. , 2009, American journal of physiology. Endocrinology and metabolism.

[91]  Wei Zhang,et al.  Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. , 2009, The Journal of clinical investigation.

[92]  A. Keech,et al.  Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. , 2008, Journal of the American College of Cardiology.

[93]  P. Havel,et al.  Endocrine and metabolic effects of consuming beverages sweetened with fructose, glucose, sucrose, or high-fructose corn syrup. , 2008, The American journal of clinical nutrition.

[94]  Nikolaus Marx,et al.  The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. , 2008, The American journal of cardiology.

[95]  F. Sacks,et al.  The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients , 2008, Diabetes & vascular disease research.

[96]  Christopher P Cannon,et al.  Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. , 2008, Journal of the American College of Cardiology.

[97]  J. Mann,et al.  Dietary carbohydrate: relationship to cardiovascular disease and disorders of carbohydrate metabolism , 2007, European Journal of Clinical Nutrition.

[98]  D. Karalis,et al.  Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia. , 2007, The American journal of cardiology.

[99]  B. Nordestgaard,et al.  Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. , 2007, JAMA.

[100]  P. Ridker,et al.  Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. , 2007, JAMA.

[101]  J. Danesh,et al.  Triglycerides and the Risk of Coronary Heart Disease: 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies , 2007, Circulation.

[102]  M. Briel,et al.  Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. , 2006, Archives of internal medicine.

[103]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[104]  S. Monks,et al.  Genome-wide scan for quantitative trait loci influencing LDL size and plasma triglyceride in familial hypertriglyceridemia Published, JLR Papers in Press, August 16, 2003. DOI 10.1194/jlr.M300272-JLR200 , 2003, Journal of Lipid Research.

[105]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2003 .

[106]  R. Morton,et al.  LDL and HDL enriched in triglyceride promote abnormal cholesterol transport DOI 10.1194/jlr.M100431-JLR200 , 2002, Journal of Lipid Research.

[107]  J. Hendriks,et al.  Diagnosis of Familial Combined Hyperlipidemia Based on Lipid Phenotype Expression in 32 Families: Results of a 5-Year Follow-Up Study , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[108]  J. Wittes,et al.  Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. , 2001, JAMA.

[109]  Diabetes Atherosclerosis Intervention Study Investigators.  Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study , 2001, The Lancet.

[110]  R. Morton,et al.  Elevated Triglyceride Content Diminishes the Capacity of High Density Lipoprotein to Deliver Cholesteryl Esters via the Scavenger Receptor Class B Type I (SR-BI)* , 2001, The Journal of Biological Chemistry.

[111]  Bezafibrate Infarction Prevention study.  Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. , 2000, Circulation.

[112]  L. Stavenow,et al.  Influence of serum triglyceride levels on the risk for myocardial infarction in 12,510 middle aged males: interaction with serum cholesterol. , 1999, Atherosclerosis.

[113]  H. Hein,et al.  Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. , 1998, Circulation.

[114]  W. Mack,et al.  The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[115]  J. Hokanson,et al.  Plasma Triglyceride Level is a Risk Factor for Cardiovascular Disease Independent of High-Density Lipoprotein Cholesterol Level: A Metaanalysis of Population-Based Prospective Studies , 1996, Journal of cardiovascular risk.

[116]  R. Havel,et al.  Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[117]  P. Urdal,et al.  Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women. , 1993, BMJ.

[118]  D. Jacobs,et al.  Plasma triglyceride level and mortality from coronary heart disease. , 1993, The New England journal of medicine.

[119]  A M Dattilo,et al.  Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. , 1992, The American journal of clinical nutrition.

[120]  I. Goldberg,et al.  Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. , 1990, The Journal of biological chemistry.

[121]  I. Holme,et al.  Serum triglycerides as an independent risk factor for death from coronary heart disease in middle-aged Norwegian men. , 1989, American journal of epidemiology.

[122]  B. Nordestgaard,et al.  Reduced Atherogenesis in Cholesterol‐fed Diabetic Rabbits: Giant Lipoproteins Do Not Enter the Arterial Wall , 1988, Arteriosclerosis.

[123]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[124]  R. Bawol,et al.  Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. , 1980, The New England journal of medicine.

[125]  R. Mahley,et al.  Cholesteryl ester accumulation in macrophages resulting from receptor-mediated uptake and degradation of hypercholesterolemic canine beta-very low density lipoproteins. , 1980, The Journal of biological chemistry.

[126]  A. Motulsky,et al.  Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. , 1973, The Journal of clinical investigation.

[127]  P. Barter,et al.  Dysfunctional HDL and atherosclerotic cardiovascular disease , 2016, Nature Reviews Cardiology.

[128]  M. Carbajo,et al.  Weight loss and improvement of lipid profiles in morbidly obese patients after laparoscopic one-anastomosis gastric bypass: 2-year follow-up , 2016, Surgical Endoscopy.

[129]  R. Karas,et al.  Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use. , 2008, The American journal of cardiology.